Autism Spectrum DisorderNCT07770451
Medial Prefrontal Cortex Brain Magnetic Stimulation in Autism
A study testing TMS in people with Autism Spectrum Disorder, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Despite decades of research, no definitive, effective biological treatments exist for core symptoms of Autism Spectrum Disorder (ASD). Emerging evidence suggests that conventional Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex or posterior superior temporal sulcus may reduce… Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- TMS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Dec 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Having a diagnosis of autism spectrum disorder based on DSM-5-TR diagnosis criteria
- Aged 18-45 years old
- No change of medications in the past three months
Who cannot join
- Comorbidity of schizophrenia, substance use disorder,
- Had major medical diseases (e.g., malignancy, severe cardiac, hepatic, renal diseases, or active CNS or systemic infection) or major neurological disease (e.g., uncontrolled epilepsy, brain tumors or hemangioma, severe head trauma)
- Contraindications of MRI or TMS procedure: Ferromagnetic material in the skull, head, and neck; claustrophobia; had received neurosurgery, etc.
- Receiving electroconvulsive therapy or TMS in the past three months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yi-Ting Lin, MD contact
Taiwan1 site
Department of Psychiatry, National Taiwan University Hospital
Taipei
Yi-Ling Chien, MD, PhD, 886+223123456 ext. 262380, ntuh.peers@gmail.com
About this study
Official title: The Efficacy and Brain Mechanism of Deep Transcranial Magnetic Stimulation in Autism: A Pilot Study Targeting Medial Prefrontal Cortex
Despite decades of research, no definitive, effective biological treatments exist for core symptoms of Autism Spectrum Disorder (ASD). Emerging evidence suggests that conventional Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex or posterior superior temporal sulcus may reduce repetitive behaviors, but its efficacy on social communication remains inconsistent.
Deep Transcranial Magnetic Stimulation (dTMS) allows for the stimulation of deeper brain structures. Deep social brain networks, such as the medial prefrontal cortex (mPFC), play a critical role in social cognition and mentalizing processes. Targeting the mPFC with dTMS holds potential for improving core impairments in social cognition among individuals with ASD. This pilot study aims to evaluate the efficacy of dTMS on social cognition, mPFC-related functional connectivity, and clinical symptoms (autism severity, stereotyped behaviors, sensory symptoms, and emotion regulation).
Read the detailed description
Conventional repetitive Transcranial Magnetic Stimulation (rTMS) and intermittent Theta Burst Stimulation (iTBS) targeting regions such as the dorsolateral prefrontal cortex (DLPFC) or posterior superior temporal sulcus (pSTS) have shown moderate efficacy in reducing repetitive behaviors and irritability in Autism Spectrum Disorder (ASD). However, their therapeutic effects on core social communication deficits remain inconsistent (~30% response rate in pSTS studies). A key physical limitation of standard TMS/TBS figure-of-eight coils is their shallow stimulation depth (0.7 to 1.1 cm), which restricts their ability to directly reach deeper cortical structures within the "social brain" network.Deep Transcranial Magnetic Stimulation (dTMS) utilizes specialized coil geometry (such as H-coils) to deliver magnetic fields to deeper brain structures (1.8 to 3.5 cm) over larger volumes. The medial prefrontal cortex (mPFC) is a central hub of the social brain network, playing a vital role in social cognition, emotion processing, and mentalization. Preliminary evidence suggests that targeting the mPFC/dorsomedial PFC with dTMS can improve emotion recognition, reduce self-oriented social anxiety, and alleviate core autistic symptoms in high-functioning adults. This pilot study aims to evaluate the safety, clinical efficacy, neural mechanism, and predictive biomarkers of mPFC-targeted dTMS in autistic adults.Study Objectives \& Research QuestionsThis single-arm/pilot clinical trial is designed to address the following specific research questions and objectives:Safety and Tolerability: Evaluate the overall safety, side-effect profile, and tolerability of high-frequency dTMS targeting the mPFC in adults with ASD.
Clinical Efficacy:
Assess whether 10 sessions of high-frequency dTMS lead to significant improvements in core ASD domains, with emotion recognition (social cognition) as the primary outcome measure. Secondary outcomes include overall autism severity, repetitive/stereotyped behaviors, sensory processing abnormalities, and emotional regulation.Neural Connectivity (fMRI): Utilize functional Magnetic Resonance Imaging (fMRI) to evaluate post-treatment changes in functional connectivity between the mPFC and other key nodes of the social brain network (e.g., amygdala, orbitofrontal cortex, superior temporal sulcus, anterior cingulate cortex, and temporoparietal junction). Predictive Biomarkers (EEG E/I Balance): Investigate whether acute electroencephalography (EEG) shifts in the excitation/inhibition (E/I) balance-estimated via changes in the aperiodic exponent after a single initial dTMS session-can serve as a neurophysiological biomarker to predict final clinical and neural connectivity responses.
All participants will receive the same deep rTMS intervention. Following treatment, participants will grouped into high response and low response subgroups based on changes of their aperiodic exponent before and after the single-session dTMS for further analysis.
- Conditions
- Autism Spectrum Disorder
- Being tested
- TMS
- Keywords
- autism spectrum disorder, asd, Deep Transcranial Magnetic Stimulation, dTMS, Medial Prefrontal Cortex, mPFC, brain stimulation, neuromodulation
- Medical subject headings
- Autism Spectrum Disorder, Child Development Disorders, Pervasive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TMSDevice
The TMS device (Brainsway Deep TMS system with an H1 coil device, Brainsway Ltd, Israel) emits brief, noninvasive electromagnetic pulses through the skull, inducing an electrical current in a specific cortical region to affect neuronal function. Subjects will receive 10 once-daily high-frequency repetitive TMS sessions on 10 consecutive work days. To stimulate the mPFC, the H1 coil helmet will be placed symmetrically bilaterally and with its zero mark 3 cm above the nasion on the sagittal rule. The stimulation parameters follow the standard protocol cleared by the USFDA. Each session consists of 55 trains of 2-sec 18-Hz stimulation, given every 20 sec (2-sec on and 18-second off, inter-train interval 20 sec), and the stimulation intensity is 120% resting motor threshold (rMT). As such 1980 pulses will be given in around 20 minutes each session. The rMT is the minimal stimulation intensity that can induce observable muscle contraction in at least 5 out of 10 consecutive stimulations.
| Study group | Role | What they receive |
|---|---|---|
| TMS pilot group | Experimental | Each participant will receive one session of magnetic stimulation and undergo resting-state electroencephalography (EEG) before and after stimulation.
Subsequently, they will receive magnetic stimulation once daily for 10 days, for a total of 10 sessions.
On the day of the tenth stimulation session or within three days afterward, participants will undergo post-treatment assessment and brain MRI. Receives: Device: TMS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Social cognitive performance on the "Reading the Mind in the Eyes" Test
The Reading the Mind in the Eyes Test (RMET; Baron-Cohen et al., 2001) will be used to assess recognition of emotional and mental states from facial cues. First, participants will complete the Basic Emotion Recognition Task, identifying six basic emotions-happiness, sadness, anger, fear, disgust, and surprise-from whole-face photographs using a two-choice format. They will then complete the standard RMET, which contains 36 photographs of the eye region depicting complex mental states. For each image, participants select the most appropriate of four descriptors. To examine possible cultural differences, the Taiwanese RMET (TW-RMET) is administered alongside the original UK version. The TW-RMET includes 43 culturally adapted items and has been validated in Taiwanese populations (Li et al., 2022). Higher scores indicates a stronger ability to accurately interpret emotional and mental cues from facial expressions.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Secondary outcomes (12)
The Social Responsiveness Scale (SRS)
The SRS (Constantino, 2002) is a 65-item rating scale assessing the severity of ASD symptoms in natural settings. It provides clinical description of an individual's social impairments, covering social awareness, social information processing, capacity for reciprocal social communication, social avoidance, and autistic mannerisms. Higher scores on the SRS total scores reflect greater impairment and autistic symptoms with scores≧60 typically considered within above the clinical threshold. The Mandarin Chinese version of the SRS has demonstrated strong psychometric properties, with satisfactory four-factor structure and high internal consistency (Cronbach's alpha, .94-.95), i.e., social communication, autistic mannerism, social awareness, and social emotion (Gau et al., 2013). In this project, we use the SRS to measure social communication deficits and stereotyped behaviors.
Measured: 14 days (change from baseline to after 10 working days of intervention)
The Autism-Spectrum Quotient (AQ)
The Autism-Spectrum Quotient (AQ; Baron-Cohen et al., 2001) is a 50-item self- or parent-report measure of autistic traits across social skills, attention switching, attention to detail, communication, and imagination. Items use a four-point response scale, with higher scores indicating more autistic traits. The AQ has good internal consistency (α=.82), test-retest reliability (.70), and screening validity, with a clinical threshold of 26 (Woodbury-Smith et al., 2005). The Mandarin Chinese AQ uses a 1-4 Likert scale and has been validated in Taiwanese adults (Lau et al., 2013). It shows good total-score internal consistency (α=.836), moderate-to-good test-retest reliability (ICC=.647), and somewhat different factor structure from the original version.
Measured: 14 days (change from baseline to after 10 working days of intervention)
The Ritvo Autism Asperger Diagnostic Scale-Revised (RAADS-R)
The RAADS-R (Ritvo et al., 2011) is a self-report instrument designed to assist in the identification of adult autistics older than 18 years, particularly those who may have escaped earlier diagnosis due to subclinical symptom presentation. The RAADS-R is an updated version of the original Ritvo Autism Asperger Diagnostic Scale (RAADS) (Ritvo et al., 2008). Questions on the initial RAADS assess developmental pathology in three symptom domains: language, social relatedness, and sensory-motor (of the DSM-IV-TR). The revised 80-item RAADS-R includes the addition of a fourth domain-circumscribed interests, as well as two new items and multiple wording clarifications based on clinical feedback and factor analytic findings. Subsequent factor analysis of the RAADS-R supported a four-factor structure, comprising: social-relatedness, circumscribed interests, sensory-motor behaviors, and social anxiety. Scores above 65 strongly suggest the presence of autistic traits.
Measured: 14 days (change from baseline to after 10 working days of intervention)
The Empathy Quotient (EQ)
The EQ (Baron-Cohen \& Wheelwright, 2004) is a widely used self-report measure designed to assess cognitive and affective components of empathy. Empirical evidence has demonstrated that approximately 81% of autistic individuals score below 30 on the EQ, whereas only 12% of neurotypical controls fall within this range, indicating its clinical utility in distinguishing empathic traits in ASD populations. The EQ demonstrates excellent psychometric properties, with an internal consistency of α = .92 and a test-retest reliability of r = .97. The Mandarin Chinese version of the EQ, developed and validated by Huang H.-Y. and Gau S.S.-F. (unpublished), has shown satisfactory reliability and validity and will be utilized in the current study to assess empathic functioning in autistic participants. Higher scores represent higher empathy levels, while lower indicate social and communication obstacles.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Adolescent/Adult Sensory Profile (AASP)
The AASP (Catana E. Brown, 2002) is a 60-item self-rating scale designed to examine sensory-related features, including preference, emotional reactions, or behavior changes prompted by perceptions. It measures six modalities: taste/smell, movement, visual, touch, activity, and auditory processing. It adopts a 5-point Linkert rating scale with '1' for never (0%), '2' for seldom (25%), '3' for sometimes (50%), '4' for frequently (75%), and '5' for always (100%). Aligned with Dunn's 4-dimension model of sensory functioning (Dunn, 1997; Dunn \& Brown, 1997), the scoring system includes Low Registration, Sensation Seeking, Sensory Sensitivity, and Sensation Avoiding subscales, where higher scores indicate greater sensory reactivity. The Mandarin version of the AASP has been validated in Taiwanese populations, showing acceptable internal consistency (Cronbach's α = 0.71-0.80) and strong test-retest reliability (intraclass correlation coefficients = 0.80-0.86) (Tseng MH, 2009).
Measured: 14 days (change from baseline to after 10 working days of intervention)
Sensory Perception Quotient (SPQ-10)
The 10-item short SPQ, SPQ-10 (Greenberg et al., 2018) is a brief, self-report instrument designed to assess sensory hypersensitivity across five sensory modalities: vision, hearing, touch, taste, and smell. The scale includes two items per modality, and each item is rated on a 4-point Likert scale ranging from 0 (strongly disagree) to 3 (strongly agree). The total score, obtained by summing responses to all items, provides an overall index of sensory hypersensitivity, with higher scores indicating greater sensitivity. The SPQ-10 has demonstrated strong convergent validity, with high negative correlations reported with both the full-length SPQ (r = -0.828, p < 0.01) and the 35-item short version (r = -0.920, p < 0.01) (Greenberg et al., 2018), supporting its construct validity and efficiency as a screening tool. The Mandarin Chinese has been validated by our research team (paper in press).
Measured: 14 days (change from baseline to after 10 working days of intervention)
The Schutte Emotional Intelligence Scale (SEIS)
The SEIS is a 33-item self-report inventory designed to assess various components of emotional intelligence. Factor analytic studies have supported a four-factor structure for the SEIS encompassing the following domains: (Ciarrochi et al., 2001; Petrides \& Furnham, 2000; Saklofske et al., 2003), including perception of emotions, managing emotions in the self, social skills or managing others' emotions, and utilizing emotions. The SEIS was translated into Mandarin Chinese in a previous project conducted by our team, and its psychometric properties have been validated in a Taiwanese sample (Chien et al., 2023).
Measured: 14 days (change from baseline to after 10 working days of intervention)
The Social Interaction Anxiety Scale (SIAS) (Mattick & Clarke, 1998)
This 20-item self-report scale measures social anxiety experienced in social situations based on DSM-IV criteria of social anxiety disorder. Respondents rate each item on a 5-point Likert scale, ranging from 0 (not at all characteristic of me) to 4 (extremely characteristic of me), yielding a total score between 0 and 80, with higher scores indicating greater levels of social anxiety. The Chinese version of the SIAS (Yang, 2003), has demonstrated adequate psychometric properties, including good internal consistency and construct validity. It has been widely used in both clinical and community samples in Chinese-speaking populations. In this project, the SIAS will be employed as a measure of social anxiety severity to evaluate potential changes before and after intervention.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Beck Depression Inventory (BDI)
The BDI (Beck et al., 1961) is a 21-item self-report instrument measuring the severity of depression in adolescents and adults. The BDI-II (Beck et al., 1996) was revised in 1996 to be more consistent with the DSM-IV criteria for major depressive disorder. Each item is rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (severe), producing a total score from 0 to 63, with higher scores reflecting greater depressive symptomatology. A Mandarin Chinese version of the BDI was translated and validated by Zheng et al. (1988). This version demonstrated good internal consistency (Cronbach's α = 0.85) and acceptable concurrent validity with clinical measures (r = 0.566), supporting its applicability in Chinese-speaking populations.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Beck Anxiety Inventory (BAI)
The BAI (Beck et al., 1988) is a 21-item self-report questionnaire designed to assess the severity of anxiety symptoms experienced over the past month. The scale encompasses multiple dimensions of anxiety, including autonomic, neurophysiological, panic-related, and subjective components. Respondents rate each item on a 4-point Likert scale, ranging from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. The Mandarin Chinese version of the BAI was adapted by Luo et al. (2004) and further validated in clinical populations with anxiety disorders. Its psychometric properties have been well established, demonstrating high internal consistency (Cronbach's α = 0.95) and good construct validity (Che et al., 2006).
Measured: 14 days (change from baseline to after 10 working days of intervention)
WHO Quality of Life (WHOQOL-BREF)
The WHOQOL-100 was originally developed by the WHOQOL research group as a comprehensive instrument to evaluate quality of life across diverse cultural settings. A shorter version, the WHOQOL-BREF, was later developed to enhance feasibility in clinical and research contexts (The WHOQOL Group, 1998). The WHOQOL-BREF comprises 28 items, covering four major domains: physical health (7 items), psychological health (6 items), social relationships (3 items), and environment (8 items). In addition, it includes two general items assessing overall quality of life and general satisfaction with health A Taiwanese version of the WHOQOL-BREF has been developed and culturally adapted. Each item is rated on a five-point Likert scale ranging from 1 (very dissatisfied/poor) to 5 (very satisfied/good), with higher scores indicating better perceived quality of life.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Resting-state functional connectivity of the mPFC on the MRI
Images will be acquired using a Siemens MAGNETOM Trio 3.0 Tesla. High resolution T1 structural image will serve for frameless stereotaxy navigation of TMS experiments. For the resting-state functional imaging, subjects will be instructed to remain awake with their eyes open. Forty-seven contiguous horizontal slices parallel to the intercommissural plane will be acquired by using a gradient echo T2*-weighted sequence (TR 2500 msec, TE 30 msec, flip angle 90°). The Statistical Parametric Mapping 12 (SPM12, Wellcome Centre for Human Neuroimaging, University College London, UK) and the SPMbased CONN (Whitfield-Gabrieli \& Nieto-Castanon, 2012) will be used to preprocess and analyze the fMRI data. The preprocessing consists of realignment and unwrapping of the functional data, slice-timing correction, outlier identification, direct segmentation and normalization of functional and anatomical data, functional smoothing, and denoising by linear regression and temporal band-pass filtering.
Measured: 14 days (change from baseline to after 10 working days of intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start1 Dec 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07770451
- Sponsor's protocol ID
- 202508055DINA
- Status last verified
- Jul 2026
- First submitted
- 3 Aug 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Brain Mechanism of Deep Transcranial Magnetic Stimulation in Autism: A Pilot Study Targeting Medial Prefrontal Cortex
- ClinicalTrials.gov ID
- NCT07770451
- Acronym / sponsor ID
- 202508055DINA
- Conditions
- Autism Spectrum Disorder
- Keywords
- autism spectrum disorder, asd, Deep Transcranial Magnetic Stimulation, dTMS, Medial Prefrontal Cortex, mPFC, brain stimulation, neuromodulation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite decades of research, no definitive, effective biological treatments exist for core symptoms of Autism Spectrum Disorder (ASD). Emerging evidence suggests that conventional Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex or posterior superior temporal sulcus may reduce repetitive behaviors, but its efficacy on social communication remains inconsistent.
Deep Transcranial Magnetic Stimulation (dTMS) allows for the stimulation of deeper brain structures. Deep social brain networks, such as the medial prefrontal cortex (mPFC), play a critical role in social cognition and mentalizing processes. Targeting the mPFC with dTMS holds potential for improving core impairments in social cognition among individuals with ASD. This pilot study aims to evaluate the efficacy of dTMS on social cognition, mPFC-related functional connectivity, and clinical symptoms (autism severity, stereotyped behaviors, sensory symptoms, and emotion regulation).
Detailed description
Conventional repetitive Transcranial Magnetic Stimulation (rTMS) and intermittent Theta Burst Stimulation (iTBS) targeting regions such as the dorsolateral prefrontal cortex (DLPFC) or posterior superior temporal sulcus (pSTS) have shown moderate efficacy in reducing repetitive behaviors and irritability in Autism Spectrum Disorder (ASD). However, their therapeutic effects on core social communication deficits remain inconsistent (~30% response rate in pSTS studies). A key physical limitation of standard TMS/TBS figure-of-eight coils is their shallow stimulation depth (0.7 to 1.1 cm), which restricts their ability to directly reach deeper cortical structures within the "social brain" network.Deep Transcranial Magnetic Stimulation (dTMS) utilizes specialized coil geometry (such as H-coils) to deliver magnetic fields to deeper brain structures (1.8 to 3.5 cm) over larger volumes. The medial prefrontal cortex (mPFC) is a central hub of the social brain network, playing a vital role in social cognition, emotion processing, and mentalization. Preliminary evidence suggests that targeting the mPFC/dorsomedial PFC with dTMS can improve emotion recognition, reduce self-oriented social anxiety, and alleviate core autistic symptoms in high-functioning adults. This pilot study aims to evaluate the safety, clinical efficacy, neural mechanism, and predictive biomarkers of mPFC-targeted dTMS in autistic adults.Study Objectives \& Research QuestionsThis single-arm/pilot clinical trial is designed to address the following specific research questions and objectives:Safety and Tolerability: Evaluate the overall safety, side-effect profile, and tolerability of high-frequency dTMS targeting the mPFC in adults with ASD.
Clinical Efficacy:
Assess whether 10 sessions of high-frequency dTMS lead to significant improvements in core ASD domains, with emotion recognition (social cognition) as the primary outcome measure. Secondary outcomes include overall autism severity, repetitive/stereotyped behaviors, sensory processing abnormalities, and emotional regulation.Neural Connectivity (fMRI): Utilize functional Magnetic Resonance Imaging (fMRI) to evaluate post-treatment changes in functional connectivity between the mPFC and other key nodes of the social brain network (e.g., amygdala, orbitofrontal cortex, superior temporal sulcus, anterior cingulate cortex, and temporoparietal junction). Predictive Biomarkers (EEG E/I Balance): Investigate whether acute electroencephalography (EEG) shifts in the excitation/inhibition (E/I) balance-estimated via changes in the aperiodic exponent after a single initial dTMS session-can serve as a neurophysiological biomarker to predict final clinical and neural connectivity responses.
All participants will receive the same deep rTMS intervention. Following treatment, participants will grouped into high response and low response subgroups based on changes of their aperiodic exponent before and after the single-session dTMS for further analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TMS pilot group | Experimental | Device: TMSEach participant will receive one session of magnetic stimulation and undergo resting-state electroencephalography (EEG) before and after stimulation. Subsequently, they will receive magnetic stimulation once daily for 10 days, for a total of 10 sessions. On the day of the tenth stimulation session or within three days afterward, participants will undergo post-treatment assessment and brain MRI. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Having a diagnosis of autism spectrum disorder based on DSM-5-TR diagnosis criteria
- Aged 18-45 years old
- No change of medications in the past three months
Key exclusion criteria (4 listed)
- Comorbidity of schizophrenia, substance use disorder,
- Had major medical diseases (e.g., malignancy, severe cardiac, hepatic, renal diseases, or active CNS or systemic infection) or major neurological disease (e.g., uncontrolled epilepsy, brain tumors or hemangioma, severe head trauma)
- Contraindications of MRI or TMS procedure: Ferromagnetic material in the skull, head, and neck; claustrophobia; had received neurosurgery, etc.
- Receiving electroconvulsive therapy or TMS in the past three months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TMSThe TMS device (Brainsway Deep TMS system with an H1 coil device, Brainsway Ltd, Israel) emits brief, noninvasive electromagnetic pulses through the skull, inducing an electrical current in a specific cortical region to affect neuronal function. Subjects will receive 10 once-daily high-frequency repetitive TMS sessions on 10 consecutive work days. To stimulate the mPFC, the H1 coil helmet will be placed symmetrically bilaterally and with its zero mark 3 cm above the nasion on the sagittal rule. The stimulation parameters follow the standard protocol cleared by the USFDA. Each session consists of 55 trains of 2-sec 18-Hz stimulation, given every 20 sec (2-sec on and 18-second off, inter-train interval 20 sec), and the stimulation intensity is 120% resting motor threshold (rMT). As such 1980 pulses will be given in around 20 minutes each session. The rMT is the minimal stimulation intensity that can induce observable muscle contraction in at least 5 out of 10 consecutive stimulations. | Device | TMS pilot group |
Primary outcome
Social cognitive performance on the "Reading the Mind in the Eyes" Test
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Reading the Mind in the Eyes Test (RMET; Baron-Cohen et al., 2001) will be used to assess recognition of emotional and mental states from facial cues. First, participants will complete the Basic Emotion Recognition Task, identifying six basic emotions-happiness, sadness, anger, fear, disgust, and surprise-from whole-face photographs using a two-choice format. They will then complete the standard RMET, which contains 36 photographs of the eye region depicting complex mental states. For each image, participants select the most appropriate of four descriptors. To examine possible cultural differences, the Taiwanese RMET (TW-RMET) is administered alongside the original UK version. The TW-RMET includes 43 culturally adapted items and has been validated in Taiwanese populations (Li et al., 2022). Higher scores indicates a stronger ability to accurately interpret emotional and mental cues from facial expressions.
12 secondary outcomes
The Social Responsiveness Scale (SRS)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Autism-Spectrum Quotient (AQ)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Ritvo Autism Asperger Diagnostic Scale-Revised (RAADS-R)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Empathy Quotient (EQ)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Adolescent/Adult Sensory Profile (AASP)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Sensory Perception Quotient (SPQ-10)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Schutte Emotional Intelligence Scale (SEIS)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
The Social Interaction Anxiety Scale (SIAS) (Mattick & Clarke, 1998)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Beck Depression Inventory (BDI)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Beck Anxiety Inventory (BAI)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
WHO Quality of Life (WHOQOL-BREF)
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Resting-state functional connectivity of the mPFC on the MRI
Time frame: 14 days (change from baseline to after 10 working days of intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Autism Spectrum Disorder
Recruiting
Effectiveness of Clown Therapy in Facilitating Dental Visits for Children With Autism Spectrum Disorder
Autism Spectrum Disorder (ASD
Recruiting
Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project
Autism Spectrum Disorder
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Not yet recruiting
Transdiagnostic Sleep and Circadian Treatment for Autistic Adolescents
Sleep, Autism Spectrum Disorder
RecruitingObservational study
Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare
Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yi-Ting Lin, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TMS in people with Autism Spectrum Disorder, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yi-Ling Chien, MD, PhD (866+223123456 ext. 262380, ntuh.peers@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Social cognitive performance on the "Reading the Mind in the Eyes" Test (time frame: 14 days (change from baseline to after 10 working days of intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.